Okamoto, Saori <br/><br/>
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.  [electronic resource] 

 -  Brain tumor pathology  Apr 2016 
 - 129-36 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1861-387X 
<br/><br/><label>Standard No.: </label>10.1007/s10014-016-0248-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Becaplermin<br/>Bevacizumab--pharmacology<br/>Brain Neoplasms--blood supply<br/>Combined Modality Therapy<br/>Fatal Outcome<br/>Fibroblast Growth Factor 2--genetics<br/>Gene Expression--drug effects<br/>Glioma--blood supply<br/>Humans<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Neoplasm Recurrence, Local<br/>Proto-Oncogene Proteins c-sis--genetics<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--genetics<br/>Vascular Endothelial Growth Factor Receptor-1--genetics